在晚期扩张性心肌病中成功使用免疫吸附疗法:一个病例报告
Rendan Zhang1,2, Lvwen Ning1,2, Ying Liu1,2
1Department of Geriatrics, Shenzhen Longhua District Central Hospital, Shenzhen, Guang Dong, P.R. China.
Medicine
|January 10, 2026
概括
免疫吸附 (IA) 可能有利于患有晚期,耐火性扩张性心肌病 (DCM) 的患者. 这个案例显示IA改善了治疗耐药DCM患者的症状和心脏功能.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
背景情况:
- 扩张性心肌病 (DCM) 是心力衰竭的主要原因.
- 一些DCM患者对标准治疗没有反应.
- 免疫吸附 (IA) 是一种试验性疗法,用于去除自身抗体.
研究的目的:
- 为了说明IA在先进的,耐治疗的DCM中的潜在好处.
- 介绍一个严重DCM的患者IA的案例研究.
主要方法:
- 一名患有晚期DCM且症状恶化,尽管接受了医疗治疗的患者接受了治疗.
- 患者接受了两次免疫吸附 (IA) 治疗.
- 高剂量静脉注射免疫球蛋白 (IVIG) 在IA后被使用.
主要成果:
- 在IA和IVIG之后,患者的症状有所改善.
- 亲国民生产总值水平显著下降.
- 左心室喷射分数 (LVEF) 从22-24%增加到29.2%.
结论:
- 免疫吸附可能是耐火性DCM的有益辅助疗法.
- 试验结果显示IA是有前途的,但需要在更大的研究中进行进一步的研究.
- 这一案例突出了严重心力衰竭的潜在新治疗途径.
相关概念视频
Cardiomyopathy II: Dilated Cardiomyopathy
455
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
455
Cardiomyopathy V: Interprofessional Care
326
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
326
Cardiomyopathy III: Hypertrophic Cardiomyopathy
387
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
387
Cardiomyopathy IV: Restrictive Cardiomyopathy
439
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
439
Myocarditis III: Medical Management
168
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
168
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K


